Primary cardiac lymphoma with central nervous system relapse

Rooijen, Cleo R van; Scholtens, Asbjørn M.; Jong, Cornelis N. de; Saraber, Colette E; Donk, Niels W.C.J. van de

doi:10.1002/ccr3.1094

Cited by 9 publications

(6 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Secondly, cardiovascular comorbidities are not included in the SEER database, and we were unable to further explore the impact of cardiovascular comorbidities on CVD in PCNSL patients. Recent study by Michael Brendan Cloney et al (43) found that cardiac risk predicted systemic complications among patients with PCNSL, and the PCNSL patients with resection had higher cardiac risk, but it is still unclear whether this risk is related to surgical resection or disease itself. A case report of Cleo R van Rooijen et al (44) found that primary cardiac lymphoma had a high risk of central nervous system recurrence, suggesting that cardiovascular system (e.g., heart, etc) may be potentially affected in PCNSL patients, which may cause various cardiovascular abnormalities and poor prognosis.…”

Section: Study Limitationsmentioning

confidence: 99%

“…Recent study by Michael Brendan Cloney et al. ( 43 ) found that cardiac risk predicted systemic complications among patients with PCNSL, and the PCNSL patients with resection had higher cardiac risk, but it is still unclear whether this risk is related to surgical resection or disease itself. A case report of Cleo R van Rooijen et al.…”

Section: Study Limitationsmentioning

confidence: 99%

See 1 more Smart Citation

Cardiovascular Death Risk in Primary Central Nervous System Lymphoma Patients Treated With Chemotherapy: A Registry-Based Cohort Study

Guan

Qiu

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

PurposeTo study the cardiovascular death (CVD) risk in primary central nervous system lymphoma (PCNSL) patients with chemotherapy.MethodsWe obtained 2,020 PCNSL participants and 88,613 non-central nervous system lymphoma (NCNSL) participants with chemotherapy from Surveillance, Epidemiology, and End Results (SEER) database from 2004 to 2015. A 1:3 propensity score matching (PSM) was used to reduce the imbalance between PCNSL participants with and without chemotherapy, as well as the imbalance between PCNSL and NCNSL participants with chemotherapy. Competing risks regressions were conducted to evaluate the independent influence of chemotherapy on CVD.ResultsAfter 1:3 PSM, the CVD risk in PCNSL patients with chemotherapy was lower than those without chemotherapy [decreased 53%, adjusted HR, 0.469 (95% CI, 0.255–0.862; P = 0.015)] as well as NCNSL patients with chemotherapy [decreased 36%, adjusted HR in model 1, 0.636 (95% CI, 0.439–0.923; P = 0.017)]. The CVD risk of chemotherapy decreased in PCNSL patients with age at diagnosis >60 years old [adjusted HR, 0.390 (95% CI, 0.200–0.760; P = 0.006)], and those patients diagnosed at 2010 to 2015 [adjusted HR, 0.339 (95% CI, 0.118–0.970; P = 0.044)].ConclusionPCNSL patients with chemotherapy are associated with lower CVD risk. Our findings may provide new foundations for that chemotherapy is the first-line treatment for PCNSL patients, according to a cardiovascular risk perspective.

show abstract

Section: Study Limitationsmentioning

confidence: 99%

Section: Study Limitationsmentioning

confidence: 99%

Cardiovascular Death Risk in Primary Central Nervous System Lymphoma Patients Treated With Chemotherapy: A Registry-Based Cohort Study

Guan

Qiu

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Although it is mostly seen with cardiac symptoms, it can also occur asymptomatically. Generally, clinical manifestation occurs with right ventricular dysfunction and tamponade, which also carry important clues for central nervous system involvement [16].…”

Section: Discussionmentioning

confidence: 99%

Recurrence of lymphoma with isolated pericardial mass: a case report

Serin¹,

Ulusoy²,

Onar³

et al. 2020

J Med Case Reports

View full text Add to dashboard Cite

Background Diffuse large B-cell lymphoma is the most common subtype of non-Hodgkin lymphoma and may occur with lymph node and/or extranodal involvement. Recurrence in patients with diffuse large B-cell lymphoma usually occurs within the first few years after treatment and may occur in a different area outside the initial localization. Case presentation A female Turkish patient who was diagnosed with nodular sclerosing Hodgkin lymphoma through lymphadenopathy examination reached remission after chemotherapy and radiotherapy. In the 11th year of follow-up and at the age of 45, newly developed multiple lymphadenopathies were diagnosed with a pathological result of diffuse large B-cell lymphoma in her advanced examination. Due to massive splenomegaly and cystic necrotic splenic residues, splenectomy was performed after eight cycles of a first-line chemotherapy regimen and two cycles of high-dose methotrexate treatment for central nervous system prophylaxis. A pericardial mass (maximum standardized uptake value 34.8), which was not present at the time of diagnosis and interim evaluation of positron emission tomography/computed tomography, was detected through chest pain in the third month after the last screening, although a complete response had been obtained. Pathological examination of the pericardial area revealed the pathological result was a recurrence. Conclusions Patients with diffuse large B-cell lymphoma have an aggressive clinical course, but cardiac involvement is very rare. In our patient’s case, pericardial involvement was observed after treatment and scanning revealed that recurrence took place in an area different from the pericardium. Cooperation of clinicians and pathologists and rapid evaluation are very important in cases of diffuse large B-cell lymphoma relapse. Although a tumoral invasion of the pericardium mostly suggests secondary malignancies, it should be kept in mind that recurrence of lymphoma is also possible.

show abstract

“…Prophylaxis with intrathecal chemotherapy has resulted in varied outcomes 31,32. It is currently unknown the efficacy of CNS prophylaxis at CNS relapse, and the debate on the optimal route of CNS prophylaxis (intrathecal versus systemic) is still ongoing 14. Patient’s status may be the most critical factor for therapeutic efficacy, which should be accurately evaluated.…”

Section: Discussionmentioning

confidence: 99%

“…In order to improve the diagnostic efficacy, there is emerging interest in finding new biomarkers, such as circulating tumor cells (CTC), proteins, as well as micro-RNA and DNA 7,12,13. CNS disease typically developed within a few months before the initial clinical presentation, raising the question: whether occult CNS localization was already present at the time of diagnosis 14. The BBB and the blood-cerebrospinal- fluid barrier (BCSFB) are the effective barriers to inhibit large molecules and cells into the CNS.…”

Section: Introductionmentioning

confidence: 99%

<p>Biomarkers Reflecting The Destruction Of The Blood-Brain Barrier Are Valuable In Predicting The Risk Of Lymphomas With Central Nervous System Involvement</p>

et al. 2019

OTT

View full text Add to dashboard Cite

ObjectiveWe aimed to identify the biomarkers in cerebrospinal fluid (CSF) that facilitate the diagnosis of lymphomas with central nervous system (CNS) involvement.MethodsFour cases of non-Hodgkin’s lymphoma (NHL) patients with/without CNS involvement were enrolled respectively, and non-CNS tumor patients (n=3) were selected to be the controls. Lab biomarkers, cytokines, and tight junction proteins (TJs) in CSF and serum were measured.ResultsWhen comparing the CNS to non-CNS group, cytokine including MMP-9 (15.24 vs 0.36 ng/mL), CCL-2 (1922.04 vs 490.68 pg/mL), and sVCAM-1 (61.36 vs 9.00 pg/mL), TJs including OCLN (6.68 vs 2.59 pg/mL), and ZO-1 (710.04 vs 182.98 pg/mL) in CSF were significantly higher in lymphomas patients with CNS involvement than those without CNS involvement. However, serum biomarkers were not significantly elevated. Contrary to the major findings, all conventional biomarkers and MRI results showed no significant change.ConclusionCSF biomarkers affecting BBB disruption are valuable in mirroring the risk of lymphoma CNS metastasis. Further study with a larger sample size is needed to verify these biomarkers in predicting lymphoma CNS involvement.

show abstract

Primary cardiac lymphoma with central nervous system relapse

Cited by 9 publications

References 20 publications

Cardiovascular Death Risk in Primary Central Nervous System Lymphoma Patients Treated With Chemotherapy: A Registry-Based Cohort Study

Cardiovascular Death Risk in Primary Central Nervous System Lymphoma Patients Treated With Chemotherapy: A Registry-Based Cohort Study

Recurrence of lymphoma with isolated pericardial mass: a case report

<p>Biomarkers Reflecting The Destruction Of The Blood-Brain Barrier Are Valuable In Predicting The Risk Of Lymphomas With Central Nervous System Involvement</p>

Contact Info

Product

Resources

About